Targets › PMEL
1 program from 1 company in 13 trials: 7 Phase 2, 3 Phase 3, 3 Phase 1; Oncology; next expected readout Mar 2028.
Forms physiological amyloids that play a central role in melanosome morphogenesis and pigmentation. The maturation of unpigmented premelanosomes from stage I to II is marked by assembly of processed amyloidogenic fragments into parallel fibrillar sheets, which elongate the vesicle into a striated ellipsoidal shape. (UniProt, P40967)
Open in Phaseline: the race on PMEL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunocore | Tebentafusp Melanocyte protein PMEL binding agent | PMEL | Phase 3 | Advanced Melanoma; Uveal Melanoma; Melanoma (Skin); Locally Advanced Unresectable Uveal Melanoma … | Mar 2028 |
Uveal Melanoma (3) Metastatic Uveal Melanoma (3) Advanced Melanoma (2) Melanoma (Skin) (1) Locally Advanced Unresectable Uveal Melanoma (1) Mestastatic Uveal Melanoma (1) HLA-A*0201 Positive Cells Present (1) Uveal Melanoma, Metastatic (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.